{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:36:29Z","timestamp":1771065389226,"version":"3.50.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose of Review<\/jats:title>\n<jats:p>The aim of this report is to describe the main aspects of sex-related differences in non-ischemic dilated cardiomyopathies (DCM), focusing on chemotherapy-induced heart failure (HF) and investigating the possible therapeutic implications and clinical management applications in the era of personalized medicine.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Recent Findings<\/jats:title>\n<jats:p>In cardio-oncology, molecular and multimodality imaging studies confirm that sex differences do exist, affecting the therapeutic cardioprotective strategies and, therefore, the long-term outcomes. Interestingly, compelling evidences suggest that sex-specific characteristics in drug toxicity might predict differences in the therapeutic response, most likely due to the tangled interplay between cancer and HF, which probably share common underlying mechanisms.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Summary<\/jats:title>\n<jats:p>Cardiovascular diseases show many sex-related differences in prevalence, etiology, phenotype expression, and outcomes. Complex molecular mechanisms underlie this diverse pathological manifestations, from sex-determined differential gene expression to sex hormone interaction with their receptors in the heart. Non-ischemic DCM is an umbrella definition that incorporates several etiologies, including chemotherapy-induced cardiomyopathies. The role of sex as a risk factor for cardiotoxicity is poorly explored. However, understanding the various features of disease manifestation and outcomes is of paramount importance for a prompt and tailored evaluation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s11886-020-01377-z","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T04:02:27Z","timestamp":1596859347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Sex-Related Differences in Dilated Cardiomyopathy with a Focus on Cardiac Dysfunction in Oncology"],"prefix":"10.1007","volume":"22","author":[{"given":"Domenico","family":"D\u2019Amario","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Camilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Migliaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Canonico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Arcudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco Antonio","family":"Montone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josip Andjelo","family":"Borovac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,8]]},"reference":[{"key":"1377_CR1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/CIRCRESAHA.117.309711","volume":"121","author":"WJ McKenna","year":"2017","unstructured":"McKenna WJ, Maron BJ, Thiene G. Classification, epidemiology, and global burden of cardiomyopathies. Circ Res. 2017;121:722\u201330.","journal-title":"Circ Res"},{"key":"1377_CR2","doi-asserted-by":"crossref","unstructured":"Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB; American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention Circulation 2006; 113:1807\u201316.","DOI":"10.1161\/CIRCULATIONAHA.106.174287"},{"key":"1377_CR3","doi-asserted-by":"crossref","unstructured":"Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270\u20136.","DOI":"10.1093\/eurheartj\/ehm342"},{"key":"1377_CR4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrcardio.2013.105","volume":"10","author":"RE Hershberger","year":"2013","unstructured":"Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10:531\u201347.","journal-title":"Nat Rev Cardiol"},{"key":"1377_CR5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/GIM.0b013e3181f2481f","volume":"12","author":"RE Hershberger","year":"2010","unstructured":"Hershberger RE, Morales A, Siegfried JD. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med. 2010;12:655\u201367.","journal-title":"Genet Med"},{"key":"1377_CR6","doi-asserted-by":"crossref","unstructured":"Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O\u2019Connell J, et al. Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;96:841\u20132.","DOI":"10.1161\/01.CIR.93.5.841"},{"key":"1377_CR7","first-page":"579","volume":"3","author":"GS Bloomfield","year":"2015","unstructured":"Bloomfield GS, Alenezi F, Barasa FA, Lumsden R, Mayosi BM, Velazquez EJ. Human immunodeficiency virus and heart failure in low- and middle-income countries. JACC: Heart Failure. 2015;3:579\u201390.","journal-title":"JACC: Heart Failure"},{"key":"1377_CR8","doi-asserted-by":"crossref","unstructured":"Pereira Nunes MC, Beaton A, Acquatella H, Bern C, Bolger AF, Echeverr\u00eda LE, et al. Chagas cardiomyopathy: an update of current clinical knowledge and management, a scientific statement from the American Heart Association. Circulation. 2018;138:169\u2013209.","DOI":"10.1161\/CIR.0000000000000599"},{"key":"1377_CR9","doi-asserted-by":"crossref","unstructured":"Sinagra G, Fabris E, Romani S, Negri F, Stolfo D, Brun F, Merlo M. Dilated cardiomyopathy at the crossroad: multidisciplinary approach. 2019 May 18. In: Sinagra G, Merlo M, Pinamonti B, editors. Dilated cardiomyopathy: from genetics to clinical management. Cham (CH): Springer; 2019. Chapter 15.","DOI":"10.1007\/978-3-030-13864-6"},{"key":"1377_CR10","doi-asserted-by":"crossref","unstructured":"Feingold B, Mahle WT, Auerbach S, Clemens P, Domenighetti AA, Jefferies JL, et al. Management of cardiac involvement associated with neuromuscular diseases: a scientific statement from the American Heart Association. Circulation. 2017;136:200\u201331.","DOI":"10.1161\/CIR.0000000000000526"},{"key":"1377_CR11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.tcm.2018.07.012","volume":"29","author":"K Stergiopoulos","year":"2019","unstructured":"Stergiopoulos K, Lima FV. Peripartum cardiomyopathy-diagnosis, management, and long term implications. Trends Cardiovasc Med. 2019;29:164\u201373.","journal-title":"Trends Cardiovasc Med"},{"key":"1377_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15563650.2018.1497172","volume":"57","author":"P Hantson","year":"2019","unstructured":"Hantson P. Mechanisms of toxic cardiomyopathy. Clin Toxicol (Phila). 2019;57:1\u20139.","journal-title":"Clin Toxicol (Phila)"},{"key":"1377_CR13","doi-asserted-by":"crossref","unstructured":"Towbin JA, Lowe AM, Colan SD, Sleeper L, Orav EJ, Clunie S, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296:1867\u201376.","DOI":"10.1001\/jama.296.15.1867"},{"key":"1377_CR14","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","volume":"388","author":"T Vos","year":"2016","unstructured":"Vos T, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545\u2013602.","journal-title":"Lancet"},{"key":"1377_CR15","doi-asserted-by":"crossref","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095\u2013128.","DOI":"10.1016\/S0140-6736(12)61728-0"},{"key":"1377_CR16","doi-asserted-by":"crossref","unstructured":"Balmforth C, Simpson J, Shen L, Jhund PS, Lefkowitz M, Rizkala AR, et al. Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF. JACC Heart Fail. 2019;7:457\u201365.","DOI":"10.1016\/j.jchf.2019.02.015"},{"key":"1377_CR17","doi-asserted-by":"crossref","unstructured":"Saxon LA, Stevenson WG, Middlekauff HR, Fonarow G, Woo M, Moser D, et al. Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1993;72:62\u20135.","DOI":"10.1016\/0002-9149(93)90220-7"},{"key":"1377_CR18","doi-asserted-by":"crossref","unstructured":"Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016;134:579\u2013646.","DOI":"10.1161\/CIR.0000000000000455"},{"issue":"8","key":"1377_CR19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199902253400804","volume":"340","author":"DL Dries","year":"1999","unstructured":"Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999 Feb 25;340(8):609\u201316.","journal-title":"N Engl J Med"},{"key":"1377_CR20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cpcardiol.2012.07.003","volume":"38","author":"D Fairweather","year":"2013","unstructured":"Fairweather D, Cooper LT Jr, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol. 2013;38:7\u201346.","journal-title":"Curr Probl Cardiol"},{"key":"1377_CR21","doi-asserted-by":"crossref","unstructured":"Dagenais GR, Leong DP, Rangarajan S, Lanas F, Lopez-Jaramillo P, Gupta R, et al. Lancet. 2020;395:785\u201394.","DOI":"10.1016\/S0140-6736(19)32007-0"},{"key":"1377_CR22","doi-asserted-by":"publisher","unstructured":"Araujo-Gutierrez R, Ibarra-Cortez SH, Estep JD, Bhimaraj A, Guha A, Hussain I, et al. Incidence and outcomes of cancer treatment-related cardiomyopathy among referrals for advanced heart failure. Cardiooncology. 2018;4:3. https:\/\/doi.org\/10.1186\/s40959-018-0029-y.","DOI":"10.1186\/s40959-018-0029-y"},{"key":"1377_CR23","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Zamorano JL, Lancellotti P, Mu\u00f1oz DR, Aboyans V, Asteggiano R, Galderisi M, et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: \u2002The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768\u2013801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211Paper of paramount importance in definition, imaging, and management of cardiac complications in chemotherapy.","DOI":"10.1093\/eurheartj\/ehw211"},{"key":"1377_CR24","doi-asserted-by":"publisher","first-page":"117954681986644","DOI":"10.1177\/1179546819866445","volume":"13","author":"IE Perez","year":"2019","unstructured":"Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol. 2019;13:117954681986644. https:\/\/doi.org\/10.1177\/1179546819866445.","journal-title":"Clin Med Insights Cardiol"},{"key":"1377_CR25","doi-asserted-by":"crossref","unstructured":"Oliveira GH, Dupont M, Naftel D, Myers SL, Yuan Y, Tang WH, et al. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63:240\u20138.","DOI":"10.1016\/j.jacc.2013.09.040"},{"key":"1377_CR26","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","volume":"53","author":"ET Yeh","year":"2009","unstructured":"Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231\u201347.","journal-title":"J Am Coll Cardiol"},{"key":"1377_CR27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.healun.2012.03.018","volume":"31","author":"GH Oliveira","year":"2012","unstructured":"Oliveira GH, Hardaway BW, Kucheryavaya AY, Stehlik J, Edwards LB, Taylor DO. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. J Heart Lung Transplant. 2012;31:805\u201310.","journal-title":"J Heart Lung Transplant"},{"key":"1377_CR28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/hrt.2006.098814","volume":"93","author":"EB Friedrich","year":"2007","unstructured":"Friedrich EB, B\u00f6hm M. Management of end stage heart failure. Heart. 2007;93:626\u201331.","journal-title":"Heart."},{"key":"1377_CR29","doi-asserted-by":"crossref","unstructured":"Sheppard R, Bedi M, Kubota T, Semigran MJ, Dec W, Holubkov R, et al. Myocardial expression of fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. J Am Coll Cardiol. 2005;46:1036\u201342.","DOI":"10.1016\/j.jacc.2005.05.067"},{"key":"1377_CR30","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1152\/ajpheart.00783.2011","volume":"302","author":"MJ Coronado","year":"2012","unstructured":"Coronado MJ, et al. Testosterone and interleukin-1\u03b2 increase cardiac remodeling during coxsackievirus B3 myocarditis via serpin A 3n. Am J Physiol Heart Circ Physiol. 2012;302:1726\u201336.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1377_CR31","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1136\/hrt.2008.164061","volume":"95","author":"MS Cocker","year":"2009","unstructured":"Cocker MS, Abdel-Aty H, Strohm O, Friedrich MG. Age and gender effects on the extent of myocardial involvement in acute myocarditis: a cardiovascular magnetic resonance study. Heart. 2009;95:1925\u201330.","journal-title":"Heart."},{"key":"1377_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41572-019-0084-1","volume":"5","author":"H Schultheiss","year":"2019","unstructured":"Schultheiss H, Fairweather D, Caforio ALP, et al. Dilated cardiomyopathy. Nat Rev Dis Primers. 2019;5:32. https:\/\/doi.org\/10.1038\/s41572-019-0084-1.","journal-title":"Nat Rev Dis Primers"},{"key":"1377_CR33","doi-asserted-by":"crossref","unstructured":"Baldeviano GC, Barin JG, Talor MV, Srinivasan S, Bedja D, Zheng D, et al. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res. 2010;106:1646\u201355.","DOI":"10.1161\/CIRCRESAHA.109.213157"},{"key":"1377_CR34","doi-asserted-by":"crossref","first-page":"85851","DOI":"10.1172\/jci.insight.85851","volume":"1","author":"JM Myers","year":"2016","unstructured":"Myers JM, et al. Cardiac myosin-Th17 responses promote heart failure in human myocarditis. JCI Insight. 2016;1:85851.","journal-title":"JCI Insight"},{"key":"1377_CR35","doi-asserted-by":"crossref","unstructured":"Diny NL, Baldeviano GC, Talor MV, Barin JG, Ong SF, Bedja D, et al. Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated cardiomyopathy. J Exp Med. 2017;214:943\u201357.","DOI":"10.1084\/jem.20161702"},{"key":"1377_CR36","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bbi.2008.12.002","volume":"23","author":"S Frisancho-Kiss","year":"2009","unstructured":"\u2022\u2022 Frisancho-Kiss S, et al. Gonadectomy of male BALB\/c mice increases Tim-3(+) alternatively activated M2 macrophages, Tim-3(+) T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis. Brain Behav. Immun. 2009;23:649\u201357. Findings from this study suggest that sex hormones from the testis inhibit anti-inflammatory population in the heart resulting in more severe acute cardiac inflammation in males.","journal-title":"Brain Behav. Immun"},{"key":"1377_CR37","doi-asserted-by":"crossref","unstructured":"Fairweather D, Coronado MJ, Garton AE, Dziedzic JL, Bucek A, Cooper LT Jr, et al. Sex differences in translocator protein 18 kDa (TSPO) in the heart: implications for imaging myocardial inflammation. J Cardiovasc Transl Res. 2014;7:192\u2013202.","DOI":"10.1007\/s12265-013-9538-0"},{"key":"1377_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00021.2015","volume":"97","author":"V Regitz-Zagrosek","year":"2017","unstructured":"Regitz-Zagrosek V, Kararigas G. Mechanistic pathways of sex differences in cardiovascular disease. Physiol Rev. 2017;97:1\u201337.","journal-title":"Physiol Rev"},{"key":"1377_CR39","doi-asserted-by":"crossref","unstructured":"Abston ED, Barin JG, Cihakova D, Bucek A, Coronado MJ, Brandt JE, et al. IL-33 independently induces eosinophilic pericarditis and cardiac dilation: ST2 improves cardiac function. Circ Heart Fail. 2012;5:366\u201375.","DOI":"10.1161\/CIRCHEARTFAILURE.111.963769"},{"key":"1377_CR40","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1249\/00005768-199509000-00004","volume":"27","author":"RB Melchert","year":"1995","unstructured":"Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc. 1995;27:1252\u201362.","journal-title":"Med Sci Sports Exerc"},{"key":"1377_CR41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/01.RES.61.1.12","volume":"61","author":"J Scheuer","year":"1987","unstructured":"Scheuer J, Malhotra A, Schaible TF, Capasso J. Effects of gonadectomy and hormonal replacement on rat hearts. Circ Res. 1987;61:12\u20139.","journal-title":"Circ Res"},{"key":"1377_CR42","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nrcardio.2009.105","volume":"6","author":"C Vitale","year":"2009","unstructured":"Vitale C, Mendelsohn ME, Rosano GMC. Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol. 2009;6:532\u201342.","journal-title":"Nat Rev Cardiol"},{"key":"1377_CR43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cjca.2019.05.031","volume":"36","author":"A Cannat\u00e0","year":"2020","unstructured":"Cannat\u00e0 A, Fabris E, Merlo M, Artico M, Gentile P, Pio Loco C, et al. Sex differences in the long-term prognosis of dilated cardiomyopathy. Can Journal of Cardiology. 2020;36:37\u201344.","journal-title":"Can Journal of Cardiology"},{"key":"1377_CR44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213\u201320.","journal-title":"J Am Coll Cardiol"},{"key":"1377_CR45","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jchf.2018.11.019","volume":"7","author":"G Savarese","year":"2019","unstructured":"Savarese G, Vedin O, D\u2019Amario D, Uijl A, Dahlstr\u00f6m U, Rosano G, et al. Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure. JACC Heart Fail. 2019;7:306\u201317. https:\/\/doi.org\/10.1016\/j.jchf.2018.11.019.","journal-title":"JACC Heart Fail."},{"key":"1377_CR46","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jaccao.2020.02.017","volume":"2","author":"M Camilli","year":"2020","unstructured":"Camilli M, Del Buono MG, Crea F, Minotti G. Acute heart failure twenty-nine years after treatment for childhood cancer. JACC:Cardio Oncology. 2020;2:316\u20139. https:\/\/doi.org\/10.1016\/j.jaccao.2020.02.017.","journal-title":"JACC:Cardio Oncology"},{"key":"1377_CR47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12885-018-4015-4","volume":"18","author":"P Fr\u00e8res","year":"2018","unstructured":"Fr\u00e8res P, Bouznad N, Servais L, Josse C, Wenric S, Poncin A, et al. Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer. 2018;18:102.","journal-title":"BMC Cancer"},{"key":"1377_CR48","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","volume":"63","author":"B Ky","year":"2014","unstructured":"Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63:809\u201316.","journal-title":"J Am Coll Cardiol"},{"key":"1377_CR49","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","volume":"35","author":"D Zardavas","year":"2017","unstructured":"Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, et al. Role of troponins I and T and N- terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a Herceptin adjuvant study cardiac marker substudy. J Clin Oncol. 2017;35:878\u201384.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1377_CR50","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3390\/jcm8081132","volume":"8","author":"JA Borovac","year":"2019","unstructured":"Borovac JA, Glavas D, Grabovac ZS, Domic DS, D\u2019Amario D, Bozic J. Catestatin in acutely decompensated heart failure patients: insights from the CATSTAT-HF study. J Clin Med. 2019;8(8):1132. https:\/\/doi.org\/10.3390\/jcm8081132.","journal-title":"J Clin Med"},{"key":"1377_CR51","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1053\/j.seminoncol.2019.01.007","volume":"46","author":"E Howard","year":"2019","unstructured":"Howard E, Steingart RM, Armstrong GT, Lyon AR, Armenian SH, Teresa Voso M, et al. Cardiovascular events in cancer survivors. Semin Oncol. 2019;46:426\u201332.","journal-title":"Semin Oncol"},{"key":"1377_CR52","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1152\/ajpregu.00203.2006","volume":"292","author":"TC Vary","year":"2007","unstructured":"Vary TC, Kimball SR, Sumner A. Sex-dependent differences in the regulation of myocardial protein synthesis following long-term ethanol consumption. Am J Physiol Regul Integr Comp Physiol. 2007;292:778\u201387.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"1377_CR53","first-page":"3","volume":"14","author":"L Vitali Serdoz","year":"2017","unstructured":"Vitali Serdoz L, Lutman C, Cadamuro E, Barbati G, Zecchin M, Merlo M, et al. Conflicting gender-related differences in the natural history of patients with idiopathic dilated cardiomyopathy. Epidemiol Biostat Public Health. 2017;14:3.","journal-title":"Epidemiol Biostat Public Health"},{"key":"1377_CR54","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/ejhf.1216","volume":"20","author":"BP Halliday","year":"2018","unstructured":"Halliday BP, Gulati A, Ali A, Newsome S, Lota A, Tayal U, et al. Sex- and age-based differences in the natural history and outcome of dilated cardiomyopathy. Eur J Heart Fail. 2018;20:1392\u2013400.","journal-title":"Eur J Heart Fail"},{"key":"1377_CR55","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mpo.2950210704","volume":"21","author":"JH Silber","year":"1993","unstructured":"Silber JH, Jakacki RI, Larsen RL, Goldwein JW. Barber G increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol. 1993;21:477\u20139.","journal-title":"Med Pediatr Oncol"},{"key":"1377_CR56","doi-asserted-by":"crossref","unstructured":"Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738\u201343. The article provide one of the first and most comprehensive description of prospective changes of echocardiographic variables in patients exposed to doxorubicin, highlighting the importance of sex for risk stratification.","DOI":"10.1056\/NEJM199506293322602"},{"key":"1377_CR57","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood-2010-01-263764","volume":"116","author":"S Myrehaug","year":"2010","unstructured":"Myrehaug S, Pintilie M, Yun L, Crump M, Tsang RW, Meyer RM, et al. A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood. 2010;116:2237\u201340.","journal-title":"Blood."},{"key":"1377_CR58","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13293-018-0198-2","volume":"9","author":"B Meiners","year":"2018","unstructured":"Meiners B, Shenoy C, Zordoky BN. Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity. Biol Sex Differ. 2018;9:38. https:\/\/doi.org\/10.1186\/s13293-018-0198-2.","journal-title":"Biol Sex Differ"},{"key":"1377_CR59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6604456","volume":"99","author":"AA Van der Veldt","year":"2008","unstructured":"Van der Veldt AA, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2008;99:259\u201365.","journal-title":"Br J Cancer"},{"issue":"17","key":"1377_CR60","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/jnci\/djs317","volume":"104","author":"EJ Bowles","year":"2012","unstructured":"Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104(17):1293\u2013305. https:\/\/doi.org\/10.1093\/jnci\/djs317.","journal-title":"J Natl Cancer Inst"},{"key":"1377_CR61","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","volume":"19","author":"F Conforti","year":"2018","unstructured":"Conforti F, Pala L, Bagnardi V, de Pas T, Martinetti M, Viale G, et al. Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis. Lancet. 2018;19:737\u201346.","journal-title":"Lancet"},{"issue":"2","key":"1377_CR62","first-page":"182","volume":"1","author":"KR Chitturi","year":"2019","unstructured":"Chitturi KR, Xu J, Araujo-Gutierrez R, Bhimaraj A, Guha A, Hussain I, et al. Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer. J Am Coll Cardiol CardioOnc. 2019;1(2):182\u201392.","journal-title":"J Am Coll Cardiol CardioOnc"},{"key":"1377_CR63","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjcard.2015.04.064","volume":"116","author":"L Wang","year":"2015","unstructured":"Wang L, Tan TC, Halpern EF, Neilan TG, Francis SA, Picard MH, et al. Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy. Am J Cardiol. 2015;116:442\u20136.","journal-title":"Am J Cardiol"},{"key":"1377_CR64","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","volume":"7","author":"T Force","year":"2007","unstructured":"Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332\u201344.","journal-title":"Nat Rev Cancer"},{"key":"1377_CR65","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ctrv.2010.11.001","volume":"37","author":"E Senkus","year":"2011","unstructured":"Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37:300\u201311.","journal-title":"Cancer Treat Rev"},{"key":"1377_CR66","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3390\/molecules24183214","volume":"24","author":"S Wang","year":"2019","unstructured":"Wang S. Sex differences in cancer immunotherapy efficacy, biomarkers and therapeutic strategy. Molecules. 2019;24:3214.","journal-title":"Molecules."},{"key":"1377_CR67","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10741-019-09824-y","volume":"25","author":"A De Bellis","year":"2020","unstructured":"De Bellis A, De Angelis G, Fabris E, Cannat\u00e0 A, Merlo M, Sinagra G. Gender-related differences in heart failure: beyond the \u201cone-size-fits-all\u201d paradigm. Heart Fail Rev. 2020;25:245\u201355.","journal-title":"Heart Fail Rev"},{"key":"1377_CR68","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"27","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AV, Anker SD, ESC Scientific Document Group, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;27:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"1377_CR69","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"MERIT-HF Study Group","year":"1999","unstructured":"MERIT-HF Study Group. Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001\u20137.","journal-title":"Lancet."},{"key":"1377_CR70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ahj.2005.03.054","volume":"151","author":"H Krum","year":"2006","unstructured":"Krum H, Mohacsi P, Katus HA, Tendera M, Rouleau JL, Fowler MB, et al. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. Am Heart J. 2006;151:55\u201361.","journal-title":"Am Heart J."},{"key":"1377_CR71","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/clc.22725","volume":"40","author":"BA Mulder","year":"2017","unstructured":"Mulder BA, Damman K, Van Veldhuisen DJ, Van Gelder IC, Rienstra M. Heart rate and outcome in heart failure with reduced ejection fraction: differences between atrial fibrillation and sinus rhythm-a CIBIS II analysis. Clin Cardiol. 2017;40:740\u20135.","journal-title":"Clin Cardiol"},{"key":"1377_CR72","doi-asserted-by":"crossref","unstructured":"Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215\u201325.","DOI":"10.1093\/eurheartj\/ehi115"},{"key":"1377_CR73","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1161\/CIRCULATIONAHA.106.673442","volume":"115","author":"E O\u2019Meara","year":"2007","unstructured":"O\u2019Meara E, Clayton T, McEntegart MB, McMurray JJ, Pi\u00f1a IL, Granger CB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007;115:3111\u201320.","journal-title":"Circulation."},{"key":"1377_CR74","doi-asserted-by":"crossref","unstructured":"Butler J, Anand IS, Kuskowski MA, Rector T, Carson P, Cohn JN, et al. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). Congest Heart Fail. 2010;16:191\u20135.","DOI":"10.1111\/j.1751-7133.2010.00161.x"},{"key":"1377_CR75","doi-asserted-by":"crossref","unstructured":"McMurray JJ. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin- aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Fail. 2011;13:929\u201336.","DOI":"10.1093\/eurjhf\/hfr093"},{"key":"1377_CR76","first-page":"345","volume-title":"Cardiovascular health and disease in women","author":"MC Limacher","year":"1993","unstructured":"Limacher MC, Yusuf S, for the SOLVD Investigators. Gender differences in presentation, morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD): a preliminary report. In: Wenger NK, Speroff L, Packard B, editors. Cardiovascular health and disease in women. Greenwich: Le Jacq Communications; 1993. p. 345\u20138."},{"key":"1377_CR77","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"1377_CR78","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"key":"1377_CR79","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1253\/circj.CJ-19-0227","volume":"83","author":"H Tsutsui","year":"2019","unstructured":"Tsutsui H, Momomura SI, Yamashina A, Shimokawa H, Kihara Y, Saito Y, et al. Kawasaki Y; J-SHIFT Study Investigators. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure-J-SHIFT study. Circ J. 2019;83:2049\u201360.","journal-title":"Circ J"},{"key":"1377_CR80","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijcard.2016.02.074","volume":"209","author":"AH Abdul-Rahim","year":"2016","unstructured":"Abdul-Rahim AH, MacIsaac RL, Jhund PS, Petrie MC, Lees KR, McMurray JJ, et al. Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: an analysis of the Digitalis Investigation Group (DIG) trial. Int J Cardiol. 2016;209:310\u20136.","journal-title":"Int J Cardiol"},{"key":"1377_CR81","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006645","volume":"13","author":"M Fudim","year":"2020","unstructured":"Fudim M, Sayeed S, Xu H, Matsouaka RA, Heidenreich PA, Velazquez EJ, et al. Representativeness of the PIONEER-HF clinical trial population in patients hospitalized with heart failure and reduced ejection fraction. Circ Heart Fail. 2020;13:e006645.","journal-title":"Circ Heart Fail"},{"key":"1377_CR82","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/hr.2015.1","volume":"38","author":"S Ito","year":"2015","unstructured":"Ito S, Satoh M, Tamaki Y, Gotou H, Charney A, Okino N, et al. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res. 2015;38:269\u201375.","journal-title":"Hypertens Res"},{"key":"1377_CR83","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000498984","volume":"142","author":"L Vicent","year":"2019","unstructured":"Vicent L, Ayesta A, Esteban-Fern\u00e1ndez A, G\u00f3mez-Bueno M, de-Juan J, D\u00edez-Villanueva P, et al. Sex influence on the efficacy and safety of Sacubitril\/valsartan. Cardiology. 2019;142:73\u20138.","journal-title":"Cardiology."},{"key":"1377_CR84","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","volume":"50","author":"J Gu","year":"2010","unstructured":"Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligue-ros-Saylan M, Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401\u201314.","journal-title":"J Clin Pharmacol"},{"key":"1377_CR85","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1161\/01.CIR.0000132477.32438.03","volume":"109","author":"SH Rahimtoola","year":"2004","unstructured":"Rahimtoola SH. Digitalis therapy for patients in clinical heart failure. Circulation. 2004;109:2942\u20136.","journal-title":"Circulation."},{"key":"1377_CR86","doi-asserted-by":"crossref","unstructured":"Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403\u201311.","DOI":"10.1056\/NEJMoa021266"},{"key":"1377_CR87","unstructured":"Lam CSP, Arnott C, Beale AL, et al. Sex differences in heart failure. Eur Heart J. 2019;40:3859\u201368. The article focuses on differences in the outcome of digoxin use in heart failure with atrial fibrillation according to gender, with women having greater risk of death and worsening heart failure. Authors hypothesize an interaction between digoxin and hormone replacement therapy."}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-020-01377-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-020-01377-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-020-01377-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T23:29:52Z","timestamp":1628378992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-020-01377-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,8]]},"references-count":87,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1377"],"URL":"https:\/\/doi.org\/10.1007\/s11886-020-01377-z","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,8]]},"assertion":[{"value":"8 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"102"}}